Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Drugs In Development, 2022, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.
Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 46, 20, 1, 38 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 7 and 4 molecules, respectively.
Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Osteosarcoma - Overview
Osteosarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Osteosarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteosarcoma - Companies Involved in Therapeutics Development
Osteosarcoma - Drug Profiles
Osteosarcoma - Dormant Projects
Osteosarcoma - Discontinued Products
Osteosarcoma - Product Development Milestones
Featured News & Press Releases
Apr 11, 2022: Adcendo presents data on uPARAP targeting ADCs in osteosarcoma PDX models at the 2022 AACR Annual Meeting
Jan 27, 2022: OS Therapies announces nationwide open enrollment of remaining 36 to 42 patients in phase IIb trial of OST-HER2 (Listeria monocytogenes) in recurred, resected osteosarcoma
Nov 03, 2021: OS Therapies receives Rare Pediatric Disease Designation (RDD) in osteosarcoma for OST-HER2 (Listeria monocytogenes)
Oct 25, 2021: OS Therapies doses first subject in Phase IIb osteosarcoma therapy trial
Jun 23, 2021: Children's Cancer Research Fund supports AOST-2121 PhIIb clinical trial in recurred, resected osteosarcoma
Apr 26, 2021: Advaxis announces achievement of second milestone under ADXS-HER2 licensing agreement with OS Therapies
Mar 09, 2021: Allarity Therapeutics announces positive data from preclinical study of dovitinib in osteosarcoma
Feb 05, 2021: WPD Pharmaceuticals' licensor announces 100% survival achieved in osteosarcoma lung metastases animal model of annamycin drug
Feb 02, 2021: Moleculin announces 100% survival achieved in osteosarcoma lung metastases animal model
Jan 26, 2021: OS Therapies receives trial approval from Children's Oncology Group for AOST2121 / OST31-164-01 an open-label Phase 2 study of maintenance therapy with OST31-164 after resection of recurrent osteosarcoma
Jan 19, 2021: Advaxis announces receipt of funding milestone payment under ADXS-HER2 licensing agreement with OS Therapies
Nov 23, 2020: Hillstream BioPharma's HSB-888 receives rare pediatric disease designation and orphan drug designation for osteosarcoma
Nov 19, 2020: Eisai to present new investigational data on LENVIMA (lenvatinib) in thyroid cancer and osteosarcoma at ESMO Asia 2020
Sep 24, 2020: Innova Therapeutics receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for IVT-8086 for the treatment of Osteosarcoma
Sep 11, 2020: Eisai to present abstracts on lenvatinib mesylate at ESMO Virtual Congress 2020
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Osteosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Osteosarcoma - Pipeline by Aadi Bioscience Inc, 2022
Osteosarcoma - Pipeline by Actuate Therapeutics Inc, 2022
Osteosarcoma - Pipeline by ADCendo ApS, 2022
Osteosarcoma - Pipeline by Advanced BioDesign, 2022
Osteosarcoma - Pipeline by Advaxis Inc, 2022
Osteosarcoma - Pipeline by Advenchen Laboratories LLC, 2022
Osteosarcoma - Pipeline by Allarity Therapeutics A/S, 2022
Osteosarcoma - Pipeline by Anagenics Ltd, 2022
Osteosarcoma - Pipeline by AntiCancer Inc, 2022
Osteosarcoma - Pipeline by APEIRON Biologics AG, 2022
Osteosarcoma - Pipeline by API Co Ltd, 2022
Osteosarcoma - Pipeline by Astex Therapeutics Ltd, 2022
Osteosarcoma - Pipeline by AstraZeneca Plc, 2022
Osteosarcoma - Pipeline by Atlanthera, 2022
Osteosarcoma - Pipeline by Aurora BioPharma Inc, 2022
Osteosarcoma - Pipeline by Autolus Therapeutics Plc, 2022
Osteosarcoma - Pipeline by Bayer AG, 2022
Osteosarcoma - Pipeline by Bicycle Therapeutics Plc, 2022
Osteosarcoma - Pipeline by BioAtla Inc, 2022
Osteosarcoma - Pipeline by BioEclipse Therapeutics Inc, 2022
Osteosarcoma - Pipeline by BioMarck Pharmaceuticals Ltd, 2022
Osteosarcoma - Pipeline by BioMed Valley Discoveries Inc, 2022
Osteosarcoma - Pipeline by Boehringer Ingelheim International GmbH, 2022
Osteosarcoma - Pipeline by BrightPath Biotherapeutics Co Ltd, 2022
Osteosarcoma - Pipeline by Bristol-Myers Squibb Co, 2022
Osteosarcoma - Pipeline by CanBas Co Ltd, 2022
Osteosarcoma - Pipeline by Cellectar Biosciences Inc, 2022
Osteosarcoma - Pipeline by Cellestia Biotech AG, 2022
Osteosarcoma - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Osteosarcoma - Pipeline by CorMedix Inc, 2022
Osteosarcoma - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Osteosarcoma - Pipeline by Curamir Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Dnatwo Inc, 2022
Osteosarcoma - Pipeline by Eisai Co Ltd, 2022
Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, 2022
Osteosarcoma - Pipeline by ENB Therapeutics LLC, 2022
Osteosarcoma - Pipeline by Epeius Biotechnologies Corp, 2022
Osteosarcoma - Pipeline by Exelixis Inc, 2022
Osteosarcoma - Pipeline by GlaxoSmithKline Plc, 2022
Osteosarcoma - Pipeline by GlycoMimetics Inc, 2022
Osteosarcoma - Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022
Osteosarcoma - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
Osteosarcoma - Pipeline by Hillstream BioPharma Inc, 2022
Osteosarcoma - Pipeline by HRYZ (ShenZhen) Biotech Co, 2022
Osteosarcoma - Pipeline by Hutchison MediPharma Ltd, 2022
Osteosarcoma - Pipeline by Idera Pharmaceuticals Inc, 2022
Osteosarcoma - Pipeline by ImmunityBio Inc, 2022
Osteosarcoma - Pipeline by Incuron, 2022
Osteosarcoma - Pipeline by Innova Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Intezyne Inc, 2022
Osteosarcoma - Pipeline by Iovance Biotherapeutics Inc, 2022
Osteosarcoma - Pipeline by Ipsen SA, 2022
Osteosarcoma - Pipeline by Isofol Medical AB, 2022
Osteosarcoma - Pipeline by Iterion Therapeutics Inc, 2022
Osteosarcoma - Pipeline by ITM Isotopen Technologien Munchen AG, 2022
Osteosarcoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Osteosarcoma - Pipeline by Joint Biosciences Ltd, 2022
Osteosarcoma - Pipeline by K-Group Beta Inc, 2022
Osteosarcoma - Pipeline by Komipharm International Co Ltd, 2022
Osteosarcoma - Pipeline by Kyowa Kirin Co Ltd, 2022
Osteosarcoma - Pipeline by MacroGenics Inc, 2022
Osteosarcoma - Pipeline by Mana Therapeutics Inc, 2022
Osteosarcoma - Pipeline by MD Biosciences GmbH, 2022
Osteosarcoma - Pipeline by MediaPharma SRL, 2022
Osteosarcoma - Pipeline by MedPacto Inc, 2022
Osteosarcoma - Pipeline by Merck & Co Inc, 2022
Osteosarcoma - Pipeline by Merck KGaA, 2022
Osteosarcoma - Pipeline by MetCure Therapeutics LLC, 2022
Osteosarcoma - Pipeline by Moleculin Biotech Inc, 2022
Osteosarcoma - Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2022
Osteosarcoma - Pipeline by Nkarta Inc, 2022
Osteosarcoma - Pipeline by Novartis AG, 2022
Osteosarcoma - Pipeline by Oncolys BioPharma Inc, 2022
Osteosarcoma - Pipeline by Oncotelic Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Osteosarcoma - Pipeline by Orgenesis Inc, 2022
Osteosarcoma - Pipeline by OS Therapies LLC, 2022
Osteosarcoma - Pipeline by Peel Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Pfizer Inc, 2022
Osteosarcoma - Pipeline by Pharma Mar SA, 2022
Osteosarcoma - Pipeline by Pimera Inc, 2022
Osteosarcoma - Pipeline by Provectus Biopharmaceuticals Inc, 2022
Osteosarcoma - Pipeline by QSAM Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Radiopharm Theranostics Ltd, 2022
Osteosarcoma - Pipeline by Reven Holdings Inc, 2022
Osteosarcoma - Pipeline by Scancell Holdings Plc, 2022
Osteosarcoma - Pipeline by Secura Bio Inc, 2022
Osteosarcoma - Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
Osteosarcoma - Pipeline by Shionogi & Co Ltd, 2022
Osteosarcoma - Pipeline by Singh Biotechnology LLC, 2022
Osteosarcoma - Pipeline by Sorrento Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Taiho Pharmaceutical Co Ltd, 2022
Osteosarcoma - Pipeline by Taithera Inc, 2022
Osteosarcoma - Pipeline by Transcode Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Umoja BioPharma Inc, 2022
Osteosarcoma - Pipeline by United Therapeutics Corp, 2022
Osteosarcoma - Pipeline by Vaccinex Inc, 2022
Osteosarcoma - Pipeline by Veana Therapeutics LLC, 2022
Osteosarcoma - Pipeline by Y-mAbs Therapeutics Inc, 2022
Osteosarcoma - Pipeline by Zentalis Pharmaceuticals Inc, 2022
Osteosarcoma - Dormant Projects, 2022
Osteosarcoma - Discontinued Products, 2022
List of Figures
Number of Products under Development for Osteosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Global Cancer Immunomodulator Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 95
The global Cancer Immunomodulator market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ ......
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 158
According to our LPI (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is forecast to a readjusted size of US$ 57240 million by 2030 with a CAGR of 22.2% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cells (CTCs) and Canc......
Global Circulating Tumor Cells Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 131
According to our LPI (LP Information) latest study, the global Circulating Tumor Cells market size was valued at US$ 1550.1 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells is forecast to a readjusted size of US$ 5942.1 million by 2030 with a CAGR of 21.2% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cells market. Circulating Tumor Cells are expected to show stable growth in the future mark......
Global Circulating Tumor Cells Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 125
According to our (Global Info Research) latest study, the global Circulating Tumor Cells market size was valued at USD 1630.5 million in 2023 and is forecast to a readjusted size of USD 5681.6 million by 2030 with a CAGR of 19.5% during review period.
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of......
Small Molecule Targeted Cancer Therapy - Global Market Insights and Sales Trends 2024
Published: 27-Dec-2023 Price: US 3350 Onwards Pages: 112
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Small Molecule Targeted Cancer Therapy, with......
Global Cancer Gene Therapy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Dec-2023 Price: US 3380 Onwards Pages: 101
Market Overview of Global Cancer Gene Therapy market:
According to our latest research, the global Cancer Gene Therapy market looks promising in the next 5 years. As of 2022, the global Cancer Gene Therapy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Gene Th......
T-Cell Immunotherapy - Global Market Insights and Sales Trends 2024
Published: 25-Dec-2023 Price: US 3350 Onwards Pages: 85
CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively.
The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach ......
Global Kaposi Sarcoma Market Status and Outlook 2023-2028
Published: 22-Dec-2023 Price: US 3160 Onwards Pages: 107
Kaposi's sarcoma is a type of cancer that forms in the lining of blood and lymph vessels. The tumors (lesions) of Kaposi's sarcoma typically appear as painless purplish spots on the legs, feet or face.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking a......
Global Cancer Immunomodulator Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 21-Dec-2023 Price: US 3380 Onwards Pages: 118
Market Overview of Global Cancer Immunomodulator market:
According to our latest research, the global Cancer Immunomodulator market looks promising in the next 5 years. As of 2022, the global Cancer Immunomodulator market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cance......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
